Project Grant R01CA293085
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$671K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
The Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Adeptrix Corp, a biotechnology company, to initiate development of a multiplexed, protein-based assay called PATH10 that will simultaneously measure protein targets across 10 major cell signaling pathways involved in cancer. This $295,230 award, with a period of performance from July 1, 2024 to December 31, 2024, will focus initially on the RAF-MEK-ERK pathway, which has a...
This $440,287 Project Grant awarded by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) aims to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This research will leverage tumor touch imprints on glass slides as a biobanking method, in combination with a multi-analyte molecular extraction protocol previously developed for forensic applications. The key products or services to be...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
The National Cancer Institute (NCI) awarded a $401,113 Cooperative Agreement grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Washington. The funding will support the development and clinical testing of the METABOCORE assay, which aims to rapidly evaluate drug sensitivity of solid tumor samples obtained through needle biopsies. The key objectives are to optimize the assay's preanalytical parameters, such as biopsy methods, transport conditions, and culture...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection...
This Project Grant award from the National Cancer Institute (under CFDA Program 93.396 - Cancer Biology Research) will provide $512,478 to the University of Washington to develop a 4D-tunable hydrogel platform for studying the impact of the tumor microenvironment on the development of colorectal cancer. The platform will leverage advanced biomaterials and light-activated hydrogels to create an architecturally and physiochemically accurate model of the colonic environment, enabling the...
This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $703,540 to Brigham & Women's Hospital to develop and optimize implantable microdevices for predicting patient response to cancer treatments. The key objectives are:
Validate the performance of the implantable microdevice technology to predict clinical response to immunotherapy and chemotherapy in head and neck cancer patients. This data will...
This $335,944 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the further development, refinement, and validation of the awardee's free-solution assay (FSA) technology and compensated interferometric reader (CIR). This novel, label-free, and solution-phase platform represents a paradigm-shifting approach to quantify molecular interactions relevant to cancer research and clinical applications. The FSA-CIR system enables...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Northeastern University will develop a novel microfluidic droplet-based platform (MDP) technology to generate and analyze a 3D biomimetic multicellular immunogenic tumor model. The key objectives are to: (1) establish multiple levels of hypoxia within the tumor-chip for parallel processing; (2) investigate spatiotemporal interaction between the tumor microenvironment's cancer...